TW200412959A - Isoquinoline compounds and medicinal use thereof - Google Patents

Isoquinoline compounds and medicinal use thereof Download PDF

Info

Publication number
TW200412959A
TW200412959A TW092132796A TW92132796A TW200412959A TW 200412959 A TW200412959 A TW 200412959A TW 092132796 A TW092132796 A TW 092132796A TW 92132796 A TW92132796 A TW 92132796A TW 200412959 A TW200412959 A TW 200412959A
Authority
TW
Taiwan
Prior art keywords
methyl
group
isoquinoline
chloro
isod
Prior art date
Application number
TW092132796A
Other languages
English (en)
Chinese (zh)
Other versions
TWI348371B (enExample
Inventor
Hisashi Matsumoto
Yasuhiro Egi
Masakazu Fujio
Shinya Inoue
Hiroyuki Satoh
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of TW200412959A publication Critical patent/TW200412959A/zh
Application granted granted Critical
Publication of TWI348371B publication Critical patent/TWI348371B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW092132796A 2002-11-22 2003-11-21 Isoquinoline compounds and medicinal use thereof TW200412959A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002340174 2002-11-22

Publications (2)

Publication Number Publication Date
TW200412959A true TW200412959A (en) 2004-08-01
TWI348371B TWI348371B (enExample) 2011-09-11

Family

ID=32375814

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092132796A TW200412959A (en) 2002-11-22 2003-11-21 Isoquinoline compounds and medicinal use thereof

Country Status (9)

Country Link
US (1) US7501412B2 (enExample)
EP (1) EP1566380B1 (enExample)
JP (1) JP4567460B2 (enExample)
AT (1) ATE540928T1 (enExample)
AU (1) AU2003284632A1 (enExample)
CA (1) CA2507027C (enExample)
ES (1) ES2376166T3 (enExample)
TW (1) TW200412959A (enExample)
WO (1) WO2004048339A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100390164C (zh) 2002-10-01 2008-05-28 三菱制药株式会社 异喹啉化合物及其医药用途
AU2004295058B9 (en) 2003-11-20 2011-06-30 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
EP1709012B1 (en) * 2003-12-05 2015-07-29 Janssen Pharmaceutica NV 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose)polymerase inhibitors
WO2005113540A1 (ja) * 2004-05-20 2005-12-01 Mitsubishi Pharma Corporation イソキノリン化合物及びその医薬用途
US8193206B2 (en) * 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US20060281712A1 (en) * 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
PT1984343E (pt) 2006-01-24 2013-05-15 Janssen Pharmaceutica Nv Benzimidazóis 2-substituída como moduladores seletivos do recetor de andrógeno (sarm)
RU2008136784A (ru) 2006-02-15 2010-03-20 Абботт Лаборэтриз (Us) Пиразолохинолоновые соединения, фармацевтическая композиция на их основе, способ ингибирования поли(адф-рибоза)полимеразы (parp) и способы лечения воспаления, сепсиса, септического шока и рака
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ES2506090T3 (es) * 2006-12-28 2014-10-13 Abbvie Inc. Inhibidores de la (ADP-ribosa) polimerasa
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
WO2008091555A2 (en) 2007-01-22 2008-07-31 Gtx, Inc. Nuclear receptor binding agents
HRP20120346T1 (hr) 2007-03-08 2012-05-31 Janssen Pharmaceutica N.V. Derivati kinolinona kao parp i tank inhibitori
PL2215075T3 (pl) * 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
CA2728466A1 (en) 2008-06-19 2009-12-23 Wyeth Llc Thienyl- and furanyl-isoquinolinones and methods for using them
SA109300394B1 (ar) * 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
WO2010029048A1 (en) * 2008-09-09 2010-03-18 Sekmed Srl 1, 2, 5-thiadiazole derivatives useful as immune potentiators
TW201021855A (en) * 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
TWI499418B (zh) * 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉-1(2h)-酮衍生物
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
ES2601900T3 (es) 2010-05-24 2017-02-16 Hande Starlake Bioscience Co., Ltd. Derivados de pirazol
EP3044221B1 (en) * 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
WO2017013593A1 (en) 2015-07-22 2017-01-26 Lupin Limited Isoquinolinone derivatives as parp inhibitors
ES2879434T3 (es) 2015-07-23 2021-11-22 Inst Curie Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CA3096127A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
DE2121031A1 (en) 1971-04-29 1972-11-02 Dr. Karl Thomae Gmbh, 7950 Biberach Base-substd quinazolines - thrombocyte aggregation inhibitors
IT1054655B (it) 1975-08-27 1981-11-30 Lepetit Spa Derivati condensati del l isochinolina
JPS52156876A (en) * 1976-06-23 1977-12-27 Mitsui Toatsu Chem Inc Preparation of novel isoquinolone
JPS52156875A (en) * 1976-06-23 1977-12-27 Mitsui Toatsu Chem Inc Preparation of novel isoquinolone derivatives
JPS5484597A (en) 1977-12-15 1979-07-05 Yamanouchi Pharmaceut Co Ltd Novel heterocyclic compound and its preparation
DE2963332D1 (en) * 1978-05-26 1982-09-02 Lepetit Spa Pyrazolo (3,4-c) and thiazolo (5,4-c) isoquinolines, methods for preparing them, these compounds for use as antiinflammatory, cns-depressant and anti-anxiety agents and pharmaceutical compositions thereof
JPS6442472U (enExample) 1986-06-14 1989-03-14
US4808595A (en) 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
DE68920798T2 (de) 1988-08-19 1995-05-18 Warner Lambert Co Substituierte Dihydroisochinolinone und verwandte Verbindungen als Verstärker der letalen Effekte von Bestrahlung und bestimmten Chemotherapeutika; ausgewählte Verbindungen, Analoga und Verfahren.
AU8784698A (en) 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
WO1999059973A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
WO2000042025A1 (en) 1999-01-14 2000-07-20 Meiji Seika Kaisha, Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
KR20010101675A (ko) 1999-01-26 2001-11-14 우에노 도시오 2h-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
WO2001079184A1 (en) 2000-04-18 2001-10-25 Sumitomo Pharmaceuticals Company, Limited Substituted piperazine compounds
WO2002044157A2 (en) 2000-12-01 2002-06-06 Iconix Pharmaceuticals, Inc. Parb inhibitors
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
DE60218458T2 (de) * 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
CN100390164C (zh) 2002-10-01 2008-05-28 三菱制药株式会社 异喹啉化合物及其医药用途

Also Published As

Publication number Publication date
CA2507027A1 (en) 2004-06-10
AU2003284632A1 (en) 2004-06-18
EP1566380B1 (en) 2012-01-11
TWI348371B (enExample) 2011-09-11
EP1566380A1 (en) 2005-08-24
ATE540928T1 (de) 2012-01-15
ES2376166T3 (es) 2012-03-09
CA2507027C (en) 2012-05-08
JPWO2004048339A1 (ja) 2006-03-23
WO2004048339A1 (ja) 2004-06-10
JP4567460B2 (ja) 2010-10-20
EP1566380A4 (en) 2007-05-30
US20060094743A1 (en) 2006-05-04
US7501412B2 (en) 2009-03-10

Similar Documents

Publication Publication Date Title
AU2021245150B2 (en) KRAS G12C inhibitors and methods of using the same
US11058689B2 (en) Pyrrole compounds, a process for their preparation and pharmaceutical
EP1566380B1 (en) Isoquinoline compounds and medicinal use thereof
AU746586B2 (en) Quinazolinone inhibitors of cGMP phosphodiesterase
KR101812390B1 (ko) 키나제 억제제로서의 치환된 트리시클릭 벤즈이미다졸
AU2025237955A1 (en) KRAS G12C inhibitors and methods of using the same
RU2136683C1 (ru) Сконденсированные с гетероциклическим кольцом производные пиримидина
CN116723843A (zh) 用于治疗和/或预防癌症的sos1抑制剂的药物组合
CA3098574A1 (en) Kras g12c inhibitors and methods of using the same
WO2002094790A1 (en) Fused heterocyclic compound and medicinal use thereof
US20030065180A1 (en) Tricyclic protein kinase inhibitors
CN106995443A (zh) 新组合物、用途和制备它们的方法
JP2021528401A (ja) Malt1阻害剤としてのピラゾール誘導体
CZ20021949A3 (cs) Heterocyklické dihydropyrimidiny jako inhibitory draslíkových kanálků
WO2005019188A1 (ja) 縮合ピリミジン誘導体およびその用途
WO2010121164A2 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
JP2010519226A (ja) 5−ht6受容体親和性を有する6’位置換インドール及びインダゾール誘導体
CZ2000320A3 (cs) Deriváty 4-oxo-3,5­dihydro-4H-pyridazino[4,5-b]indol-1-acetamidu a farmaceutický prostředek, který je obsahuje
WO2008059238A1 (en) Benzenesulfonamide compounds as edg-1 antagonists useful in the treatment of cancer
JPH09151186A (ja) 縮合トリアゾール化合物
NZ626623B (en) New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
HK1105586A1 (en) Phthalazine derivatives as parp inhibitors

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees